FBFlorence Bucciarelli

Florence Bucciarelli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Florence Bucciarelli has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Combining Clinical and Genetic Data to Predict Response to Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients: A Precision Medicine Approach

    by Laura Ferrè, Ferdinando Clarelli, Beatrice Pignolet, Elisabetta Mascia, Marco Frasca, Silvia Santoro, Melissa Sorosina, Florence Bucciarelli, Lucia Moiola, Vittorio Martinelli, et al.

    A personalized approach is strongly advocated for treatment selection in Multiple Sclerosis patients due to the high number of available drugs. Machine learning methods proved to be valuable tools in the context of precision medicine. In the present work, we applied machine learning methods to identify a combined clinical and genetic signature of response to fingolimod that could support the prediction of drug response. Two cohorts of fingolimod-treated patients from Italy and France were enrolled and divided into training, validation, and test set. Random forest training and robust feature selection were performed in the first two sets respectively, and the independent test set was used to evaluate model performance. A genetic-only model and a combined clinical–genetic model were obtained. Overall, 381 patients were classified according to the NEDA-3 criterion at 2 years; we identified a genetic model, including 123 SNPs, that was able to predict fingolimod response with an AUROC= 0.65 in the independent test set. When combining clinical data, the model accuracy increased to an AUROC= 0.71. Integrating clinical and genetic data by means of machine learning methods can help in the prediction of response to fingolimod, even though further studies are required to definitely extend this approach to clinical applications


  • Open Access

    Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

    by Patrick Ostkamp, Anke Salmen, Béatrice Pignolet, Dennis Goerlich, Till F. M. Andlauer, Andreas Schulte-Mecklenbeck, Gabriel Gonzalez-Escamilla, Florence Bucciarelli, Isabelle Gennero, Johanna Breuer, et al.

    Background: Multiple sclerosis (MS) disease risk is associated with reduced sun exposure. This study assessed the relationship between measures of sun-exposure (vitamin D (vitD), latitude) and MS disease severity, the mechanisms of action, and effect-modification by medication and sun-sensitivity associated MC1R variants. Methods: Two multi-center cohort studies (n NationMS =946, n BIONAT =991). Outcomes were the multiple sclerosis severity score (MSSS) and the number of Gd-enhancing lesion (GELs). RNAseq of four immune cell populations before and after UV-phototherapy of five MS patients. Results: High serum vitD was associated with reduced MSSS ( P NationMS =0.021; P BIONAT =0.007) and reduced risk for disease aggravation ( P NationMS =0.032). Low latitude was associated with higher vitD, lower MSSS ( P NationMS =0.018), fewer GELs ( P NationMS =0.030) and reduced risk for aggravation ( P NationMS =0.044). The influence of latitude on disability seemed to be lacking in the subgroup of interferon-β treated patients (interaction- P BIONAT =0.042, interaction- P NationMS =0.053). In genetic analyses, for carriers of MC1R :rs1805008(T), who reported increased sensitivity towards sunlight ( P NationMS =0.038), the relationship between latitude und the number of GELs was inversed ( P NationMS =0.001). Phototherapy induced a vitD and type I interferon signature that was most apparent in the transcriptome of monocytes ( P =1×10 −6 ). Conclusion: VitD is associated with reduced MS severity and disease aggravation. This is likely driven by sun-exposure, as latitude also correlated with disability and serum vitD. However, sun-exposure might be detrimental for sun-sensitive patients. A direct induction of type I interferons through sun-exposure could explain a reduced effect of latitude in interferon-β treated patients. This could also explain opposite effects of sun-exposure in MS and the type I interferon and sun-sensitivity-associated disease Lupus.